Print this page
Wednesday, 16 April 2014 07:31

Anticoagulation news items. Week commencing 7th April 2014

Low-Dose Aspirin for Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force

Annals of Internal Medicine

This review found low-dose aspirin was associated with absolute risk reductions of 2-5% for preeclampsia (RR 0.76; 95% CI 0.62 to 0.95), 1-5% for intrauterine growth restriction (0.80; 0.65 to 0.99), and 2-4% for preterm birth (0.86; 0.76 to 0.98), depending on baseline risk.


Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation

Cochrane Database of Systematic Reviews
DTIs found to be as efficacious as VKAs for composite outcome of vascular death and ischaemic events; only dabigatran dose 150mg BD found superior to warfarin. DTIs linked to fewer major haemorrhagic events. ADRs leading to treatment discontinuation occurred more often with DTIs.


FDA approves dabigatran (Pradaxa®) for treatment and reduction in the risk of recurrent deep vein thrombosis and pulmonary embolism

Biospace Inc.
The US FDA has approved dabigatran etexilate mesylate (Pradaxa®) for the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for 5-10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.


Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children

Cochrane Database of Systematic Reviews
A single study reported imprecise effects for the risk of CVC-related thrombosis in children on a CVC anticoagulant prophylaxis regimen. The quality of the evidence was low due to the fact that the included study was clearly underpowered, hampering any conclusions.


Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study

European Heart Journal
This Swedish registry based study (n=307,351) concluded that patients with both AF and renal failure will benefit most from having the same treatment as recommended for other patients with AF, without setting a higher or lower threshold for treatment.


New SPCs: Voncento (factor VIII, von willebrand factor) 500 IU / 1200 IU and 1000 IU / 2400 IU powder and solvent for solution for injection/infusion

electronic Medicines Compendium
Two SPCs are now available for a new product - Voncento® (factor VIII, von willebrand factor).


Point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor): diagnostics consultation

National Institute for Health and Care Excellence
DRAFT NICE guidance recommends the CoaguChek XS system for self-monitoring coagulation status in people on long-term vitamin K antagonist therapy who have AF or heart valve disease if certain caveats are met. The INRatio2 PT/INR monitor is only recommended for use in research.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: